Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5774918 | 0.81 | CYP19A1 (0.39) | SIRT2CYP19A1CYP2C9CYP2C19MEN1 | |
| SCHEMBL5777551 | 0.79 | TDO2 (0.42) | SIRT2CYP19A1CYP2C9CYP2C19MEN1 | |
| SCHEMBL5774173 | 0.79 | SIRT2 (0.52) | SIRT2CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL5774064 | 0.79 | PPARA (0.42) | SIRT2CYP19A1CYP2C9CYP2C19MEN1 | |
| SCHEMBL5773427 | 0.79 | TDO2 (0.42) | SIRT2CYP19A1CYP2C9CYP2C19MEN1 | |
| SCHEMBL5771280 | 0.78 | PTGS2 (0.39) | — | |
| SCHEMBL5776248 | 0.78 | TDO2 (0.45) | SIRT2 | |
| SCHEMBL5772652 | 0.78 | MEN1 (0.52) | SIRT2CYP19A1CYP2C9CYP2C19MEN1 | |
| SCHEMBL5776652 | 0.78 | SIRT2 (0.34) | SIRT2CYP19A1CYP2C9CYP2C19MEN1 | |
| SCHEMBL5772675 | 0.76 | TSHR (0.43) | SIRT2CYP2C19MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | MOMOSE YU | 2006-04-20 | — | — | US | disclosed |
| US-7022725-B2 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-04 | — | — | US | disclosed |
| US-20040048908-A1 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-11 | — | — | US | disclosed |
| EP-1340749-A1 | ISOXAZOLE DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | INSR, GPR119, INSRR | SIRT2 1426/4885CYP19A1 117/4885CYP2C9 30/4885 |
| US-20040048908-A1 | Isoxazole derivatives | GPR119, INSR, IRS1 | SIRT2 738/4885CYP19A1 62/4885CYP2C9 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.